Pediatric Patient With Renal Cell Carcinoma Treated by Successive Antiangiogenics Drugs: A Case Report and Review of the Literature.
Antiangiogenic drugs are currently standard of care in adults with renal cell carcinoma (RCC), including translocation RCC. Although antitumor activity and toxicity profile are well known in adults, few data have been reported in children. Here we present the case of a patient diagnosed at 2 years old with a metastatic translocation RCC, consecutively treated with 5 tyrosine kinase inhibitors during 6 years. The antitumor activity and toxic effects are described, and a brief review of the literature is presented.
Departments of *Pediatric Oncology, Adolescents and Young Adults †Translational Research ‡Radiology §Pathology ¶Somatic Genetics ††INSERM U830 Research Center, Institut Curie ∥Department of Pediatric Surgery, Necker Enfants-Malades Hospital, Assistance Publique #Department of Pediatrics, University of Paris-Descartes, Sorbonne Paris Cité, Paris **Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France.
Irene
I
Jiménez
Hervé J
HJ
Brisse
Paul
P
Fréneaux
Sabine
S
Sarnacki
Jean
J
Michon
Daniel
D
Orbach
Gaelle
G
Pierron
Nathalie
N
Clément
François
F
Doz
Bernard
B
Escudier
Gudrun
G
Schleiermacher
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D002675:Child, Preschool; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases